### NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## **Health Technology Appraisal**

# Sativex as an add-on treatment of moderate to severe spasticity in multiple sclerosis

## **Revised Provisional Matrix of consultees and commentators**

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
GW Pharma / Bayer Healthcare (Sativex)	<ul> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> </ul>
Patient/carer groups	Care Quality Commission
Action on Addiction	Commissioning Support Appraisals
Afiya Trust	Service
Alliance (the)	Department of Health, Social Services
Black Health Agency	and Public Safety for Northern Ireland
Brain and Spine Foundation	Medicines and Healthcare products
Chinese National Healthy Living	Regulatory Agency
Centre	<ul> <li>National Association of Primary Care</li> </ul>
Counsel and Care	National Treatment Agency for
Equalities National Council	Substance Misuse (NTA)
<ul> <li>Leonard Cheshire Disability</li> </ul>	NHS Alliance
Multiple Sclerosis National Therapy	<ul> <li>NHS Commercial Medicines Unit</li> </ul>
Centres	NHS Confederation
Multiple Sclerosis Resource Centre	NHS Quality Improvement Scotland
Multiple Sclerosis Society	<ul> <li>Public Health Wales NHS Trust</li> </ul>
Multiple Sclerosis Trust	<ul> <li>Scottish Medicines Consortium</li> </ul>
Muslim Council of Britain	
<ul> <li>Muslim Health Network</li> </ul>	Possible comparator manufacturer(s)
<ul> <li>Royal Association for Disability &amp;</li> </ul>	Actavis (baclofen, diazepam,
Rehabilitation (RADAR)	gabapentin, tizanidine hydrochloride)
<ul> <li>South Asian Health Foundation</li> </ul>	Allergan (botulinum toxin)
Specialised Healthcare Alliance	Almus Pharmaceuticals (clonazepam,
STEPS – Charity Worldwide	diazepam)
Sue Ryder Care	<ul> <li>Arrow Generics (baclofen, diazepam, gabapentin)</li> </ul>
Professional groups	Auden McKenzie (clonazepam)
Association of British Neurologists	Cephalon (tizanidine hydrochloride)
Association of Nurses in Substance	Chemidex Pharma (baclofen)
Abuse	Consilient Health (gabapentin)
British Association for Services to	Co-Pharma (baclofen)
the Elderly	Crescent Pharma (diazepam)

National Institute for Health and Clinical Excellence

Revised Provisional Matrix for the health technology appraisal of Sativex as an add-on treatment of moderate to severe spasticity in multiple sclerosis

Issue date: December 2010

#### Consultees Commentators (no right to submit or appeal) Dalkeith Laboratories Ltd (baclofen) **British Geriatrics Society** British Neuropathological Society DDSA Pharmaceuticals (diazepam) British Society of Rehabilitative Dr Reddy's Laboratories (diazepam, Medicine tizanidine hydrochloride) Chartered Society of Physiotherapy Durbin (diazepam) College of Occupational Therapist Eisai (botulinum toxin) Institute of Neurology Focus Pharmaceuticals (baclofen) National Drug Prevention Alliance Galderma UK (botulinum toxin) **National Pharmacy Association** Hameln Pharmaceuticals (diazepam) Primary Care Neurology Society Ipsen (botulinum toxin) Kent Pharmaceuticals (baclofen, Royal College of General **Practitioners** diazepam, gabapentin, tizanidine Royal College of Nursing hydrochloride) M&A Pharmachem Ltd (diazepam) Royal College of Pathologists Merz Pharma (botulinum toxin) Royal College of Physicians Metwest Pharmaceuticals Ltd Royal Pharmaceutical Society (diazepam) Royal Society of Medicine Mylan (baclofen, diazepam, Therapists in MS (TIMS) gabapentin, tizanidine hydrochloride) United Kingdom Clinical Pharmacy Niche Generics (tizanidine Association hydrochloride) United Kingdom Multiple Sclerosis Novartis Pharmaceuticals (baclofen) **Specialist Nurse Association** (UKMSSNA) Pfizer (gabapentin) Ranbaxy (diazepam, gabapentin, tizanidine hydrochloride) Others Department of Health Ratiopharm (gabapentin) Wolverhampton City NHS PCT Relonchem (diazepam) Northumberland Tyne & Wear NHS Roche Products (clonezapam) Trust Sandoz (gabapentin, baclofen, Welsh Assembly Government diazepam) Spepharm (dantrolene) Sun Pharmaceuticals (baclofen) Teva UK (baclofen, diazepam, gabapentin, tizanidine hydrochloride) Winthrop Pharmaceuticals (gabapentin) Wockhardt UK (diazepam) Zanza Laboratories (gabapentin) Relevant research groups Cochrane Movement Disorders Group Cochrane Multiple Sclerosis Group MRC Clinical Trials Unit National Institute for Health Research Policy Research Institute on Ageing

National Institute for Health and Clinical Excellence

Revised Provisional Matrix for the health technology appraisal of Sativex as an add-on treatment of moderate

to severe spasticity in multiple sclerosis

## **Appendix B**

Consultees	Commentators (no right to submit or appeal)
	<ul><li>and Ethnicity</li><li>Research Institute for the Care of Older People</li></ul>
	<ul> <li>Evidence Review Group</li> <li>Evidence Review Group tbc</li> <li>National Institute for Health Research Health Technology Assessment Programme</li> <li>Associated Guideline Groups</li> <li>National Clinical Guideline Centre</li> </ul>
	Associated Public Health Groups  tbc

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### **Definitions:**

## Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, Care Quality Commission and NHS Alliance, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence

Revised Provisional Matrix for the health technology appraisal of Sativex as an add-on treatment of moderate

to severe spasticity in multiple sclerosis

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.